ChromaDex, Inc.

230 articles with ChromaDex, Inc.

• ChromaDex Announces Issuance of New U.S. Patent on Dihydronicotinamide Riboside (NRH) and Dihydronicotinic Acid Riboside (NARH), Further Solidifying ChromaDex as the Leader in the Nicotinamide Adenine Dinucleotide (NAD+) Precursor Space

  2/22/2023

  ChromaDex Corp., a global bioscience company dedicated to healthy aging, holds an exclusive license from Queen’s University Belfast for methods of making nicotinamide riboside and related derivatives, some of the most efficient nicotinamide adenine dinucleotide precursors, and announced it expanded this patent family with newly granted U.S. Patent 11,584,770 for purity compositions of dihydronicotinamide riboside and dihydronicotinic acid riboside.

• ChromaDex Shares Promising Findings from a Clinical Study Showcasing Combined Metabolic Activators (CMAs), Featuring Nicotinamide Riboside (NR), Improved Cognitive Functions in Alzheimer's Disease (AD) Patients

  1/31/2023

  ChromaDex Corp. announced promising findings from a first-of-its kind clinical study, as reported in the peer-reviewed journal Translational Neurodegeneration by a team of scientists led by Dr. Adil Mardinoglu.

• ChromaDex Appoints Leading Aging and Neurodegenerative Disease Researcher, Dr. Vilhelm Bohr, to its Scientific Advisory Board (SAB)

  1/12/2023

  ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced it has appointed Dr. Vilhelm (Will) Bohr, M.D., Ph.D., D.Sc. to its Scientific Advisory Board (SAB).

• ChromaDex Named Brianna Gerber Chief Financial Officer

  1/5/2023

  ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced that it has appointed Brianna Gerber to the role of Chief Financial Officer, effective January 1, 2023.

• ChromaDex Reports FDA’s Conclusion that Nicotinamide Mononucleotide (NMN) May Not Be Sold or Marketed as a Dietary Supplement in the United States

  11/11/2022

  ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, today announced that on November 4, 2022, the U.S. FDA declared nicotinamide mononucleotide (NMN) may no longer be sold or marketed as a dietary supplement in the United States since it was first investigated as a drug.

• ChromaDex Corporation Reports Third Quarter 2022 Financial Results

  11/2/2022

  ChromaDex Corp. announced financial results for the third quarter of 2022.

• ChromaDex to Report Third Quarter Financial Results on Wednesday, November 2, 2022

  10/26/2022

  ChromaDex Corp. (NASDAQ:CDXC) (“the Company”), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, November 2, 2022 at 4:30 p.m. ET to discuss its financial results for the third quarter, which ended September 30, 2022.

• ChromaDex and Nestlé Health Science Announce New Niagen® Commercial Supply Agreement and $5 Million Investment

  10/11/2022

  ChromaDex and Nestlé Health Science Announce New Niagen ® Commercial Supply Agreement and $5 Million Investment.

• ChromaDex Shares Promising Findings from Clinical Study Showcasing ​​the Safety and Tolerability of Nicotinamide Riboside (NR) in Heart Failure With Reduced Ejection Fraction

  10/4/2022

  ChromaDex Corp. announced promising findings from a clinical study, as reported in the peer-reviewed journal Journal of the American College of Cardiology : Basic to Translational Science by a team of scientists led by Dr. Kevin O’Brien, Division of Cardiology, Department of Medicine, in collaboration with Dr. Rong Tian, Mitochondria and Metabolism Center, Department of Anesthesiology and Pain Medicine, University of Washington School of Medicine, Seattle, Washington, USA.

• ChromaDex Announces Partnership with MyPharma2Go Corporation for Cross-Border Sales of Tru Niagen® and Tru Niagen® PRO into Brazil

  9/1/2022

  Brazil is the first Latin American country to now welcome Tru Niagen®, with a strategy focused on reaching both consumers and Health Care Practitioners ChromaDex Corp. announced a partnership with MyPharma2Go to conduct cross-border sales of Tru Niagen® and Tru Niagen® PRO in Brazil, the first Latin American country to welcome the brand.

• ChromaDex Corporation Reports Second Quarter 2022 Financial Results

  8/10/2022

  ChromaDex Corp. announced financial results for the second quarter of 2022. Second Quarter 2022 and Recent Highlights Total net sales were $16.7 million, with $14.5 million from Tru Niagen®, down 5% and 6% from the prior year period, respectively.

• ChromaDex to Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022

  8/2/2022

  ChromaDex Corp. announced that it will hold a conference call on Wed. August 10, 2022 at 4:30 p.m. ET to discuss its financial results for the second quarter, which ended June 30, 2022.

• ChromaDex To Host Key Opinion Leader Webinar on the Transforming Benefits of Nicotinamide Riboside (NR)

  7/7/2022

  ChromaDex Corp. announced that it will host a key opinion leader webinar on the transforming benefits of nicotinamide riboside on Wednesday, July 20, 2022 at 11:00 am Eastern Time.

• ChromaDex to Present at American Society for Nutrition (ASN), International Society of Sports Nutrition (ISSN), and Federation of American Societies for Experimental Biology (FASEB)

  6/15/2022

  ChromaDex Corp. (NASDAQ:CDXC) today announced that members of its team, a Scientific Advisory Board member and two ChromaDex External Research Program (CERP™) investigators, will be presenting at several key scientific conferences including the American Society for Nutrition.

• ChromaDex Signs Sinopharm Xingsha Agreement to Accelerate Cross-Border Sales of Tru Niagen® into Mainland China

  6/10/2022

  ChromaDex Corp. a global bioscience company dedicated to healthy aging, announced a signed distribution agreement with Sinopharm Xingsha to accelerate cross-border sales of Tru Niagen® into mainland China.

• ChromaDex to Present at the Oppenheimer’s 22nd Annual Consumer Growth and E-Commerce Conference

  6/7/2022

  ChromaDex Corp. announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting at Oppenheimer’s 22nd Annual Consumer Growth and E-Commerce Conference.

• ChromaDex Partners with Juvenis for Cross-Border Sales of Tru Niagen® into South Korea

  6/2/2022

  ChromaDex Corp. announced a partnership with Juvenis to conduct cross-border sales of Tru Niagen® in South Korea.

• ChromaDex to Present at the LD Micro Invitational

  6/1/2022

  ChromaDex Corp. announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting virtually at the 12th annual Invitational.

• ChromaDex Announces Agreement to Launch Commercial Joint Venture in Mainland China

  5/19/2022

  The signed agreement establishes beachhead to broadly market and distribute Tru Niagen® to Mainland China’s aging population ChromaDex Corp. a global bioscience company dedicated to healthy aging, announced it has entered into an agreement to establish a joint venture through its wholly owned subsidiary ChromaDex Asia Limited.

• ChromaDex Corporation Reports First Quarter 2022 Financial Results

  5/12/2022

  ChromaDex Corp. announced financial results for the first quarter of 2022.